Anxiolytics targeting GABA_A receptors: Insights on etifoxine

References

• Akk G, Shu HJ, Wang C, Steinbach JH, Zorumski CF, Covey DF, Mennerick S. 2005. Neurosteroid access to the GABAA receptor. J Neurosci. 25:11605–11613.
   PubMed Web of Science ®Google Scholar
• Ali NJ, Olsen RW. 2001. Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms. J Neurochem. 79:1100–1108.
   PubMed Web of Science ®Google Scholar
• Aouad M, Charlet A, Rodeau JL, Poisbeau P. 2009. Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3alpha-reduced neurosteroids. Pain. 147:54–59.
   PubMed Web of Science ®Google Scholar
• Aouad M, Petit-Demouliere N, Goumon Y, Poisbeau P. 2014. Etifoxine stimulates allopregnanolone synthesis in the spinal cord to produce analgesia in experimental mononeuropathy. Eur J Pain. 18:258–268.
   PubMed Web of Science ®Google Scholar
• Aouad M, Zell V, Juif PE, Lacaud A, Goumon Y, Darbon P, Lelievre V, Poisbeau P. 2014. Etifoxine analgesia in experimental monoarthritis: a combined action that protects spinal inhibition and limits central inflammatory processes. Pain. 155:403–412.
   PubMed Web of Science ®Google Scholar
• Bormann J. 1991. Electrophysiological characterization of diazepam binding inhibitor (DBI) on GABAA receptors. Neuropharmacology. 30:1387–1389.
   PubMed Web of Science ®Google Scholar
• Busquets-Garcia A, Soria-Gomez E, Redon B, Mackenbach Y, Vallee M, Chaouloff F, Varilh M, Ferreira G, Piazza PV, Marsicano G. 2017. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol Psychiatry. 22:1594–1603.
   PubMed Web of Science ®Google Scholar
• Calhoon GG, Tye KM. 2015. Resolving the neural circuits of anxiety. Nat Neurosci. 18:1394–1404.
   PubMed Web of Science ®Google Scholar
• Callachan H, Cottrell GA, Hather NY, Lambert JJ, Nooney JM, Peters JA. 1987. Modulation of the GABAA receptor by progesterone metabolites. Proc R Soc Lond B Biol Sci. 231:359–369.
   PubMed Web of Science ®Google Scholar
• Carver CM, Reddy DS. 2016. Neurosteroid structure-activity relationships for functional activation of extrasynaptic deltaGABA(A) receptors. J Pharmacol Exp Ther. 357:188–204.
   PubMed Web of Science ®Google Scholar
• Cheng VY, Martin LJ, Elliott EM, Kim JH, Mount HT, Taverna FA, Roder JC, Macdonald JF, Bhambri A, Collinson N, et al. 2006. Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci. 26:3713–3720.
   PubMed Web of Science ®Google Scholar
• Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW, Cohen JB. 2013. Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human alpha1beta3gamma2 gamma-aminobutyric acid type A (GABAA) receptor. J Biol Chem. 288:19343–19357.
   PubMed Web of Science ®Google Scholar
• Chisari M, Shu HJ, Taylor A, Steinbach JH, Zorumski CF, Mennerick S. 2010. Structurally diverse amphiphiles exhibit biphasic modulation of GABAA receptors: similarities and differences with neurosteroid actions. Br J Pharmacol. 160:130–141.
   PubMed Web of Science ®Google Scholar
• Choi YM, Kim KH. 2015. Etifoxine for pain patients with anxiety. Korean J Pain. 28:4–10.
   PubMed Web of Science ®Google Scholar
• Christian CA, Herbert AG, Holt RL, Peng K, Sherwood KD, Pangratz-Fuehrer S, Rudolph U, Huguenard JR. 2013. Endogenous positive allosteric modulation of GABA(A) receptors by diazepam binding inhibitor. Neuron. 78:1063–1074.
   PubMed Web of Science ®Google Scholar
• Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Otu FM, Howell O, Atack JR, et al. 2002. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci. 22:5572–5580.
   PubMed Web of Science ®Google Scholar
• Costa E, Guidotti A. 1991. Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci. 49:325–344.
   PubMed Web of Science ®Google Scholar
• Cottin J, Gouraud A, Jean-Pastor MJ, Dautriche AD, Boulay C, Geniaux H, Auffret M, Bernard N, Descotes J, Vial T. 2016. Safety profile of etifoxine: a French pharmacovigilance survey. Fundam Clin Pharmacol. 30:147–152.
   PubMed Web of Science ®Google Scholar
• Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y. 2003. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature. 424:938–942.
   PubMed Web of Science ®Google Scholar
• Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, Bluthmann H, Mohler H, Rudolph U. 2002. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A. 99:8980–8985.
   PubMed Web of Science ®Google Scholar
• Crestani F, Low K, Keist R, Mandelli M, Mohler H, Rudolph U. 2001. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol. 59:442–445.
   PubMed Web of Science ®Google Scholar
• de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, van Gerven JM. 2009. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol. 23:625–632.
   PubMed Web of Science ®Google Scholar
• Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, Goodacre S, Lincoln RJ, Cook SM, Conley R, et al. 2005. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci. 25:10682–10688.
   PubMed Web of Science ®Google Scholar
• do Rego JL, Vaudry D, Vaudry H. 2015. The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS One. 10:e0120473.
   PubMed Web of Science ®Google Scholar
• Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. 2008. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 33:1603–1610.
   PubMed Web of Science ®Google Scholar
• Fan J, Liu J, Culty M, Papadopoulos V. 2010. Acyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule. Prog Lipid Res. 49:218–234.
   PubMed Web of Science ®Google Scholar
• Ffrench-Mullen JM, Barker JL, Rogawski MA. 1993. Calcium current block by (-)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl- current. J Neurosci. 13:3211–3221.
   PubMed Web of Science ®Google Scholar
• Frye CA, Walf AA. 2004. Estrogen and/or progesterone administered systemically or to the amygdala can have anxiety-, fear-, and pain-reducing effects in ovariectomized rats. Behav Neurosci. 118:306–313.
   PubMed Web of Science ®Google Scholar
• Girard C, Liu S, Cadepond F, Adams D, Lacroix C, Verleye M, Gillardin JM, Baulieu EE, Schumacher M, Schweizer-Groyer G. 2008. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc Natl Acad Sci USA. 105:20505–20510.
   PubMed Web of Science ®Google Scholar
• Girard P, Pansart Y, Gillardin JM. 2009. Preventive and curative effects of etifoxine in a rat model of brain oedema. Clin Exp Pharmacol Physiol. 36:655–661.
   PubMed Web of Science ®Google Scholar
• Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Francon D, Avenet P, Schoemaker H, Evanno Y, et al. 2003. SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev. 9:3–20.
   PubMedGoogle Scholar
• Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD, Costa E. 1983. Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA. 80:3531–3535.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Garcia AG, Contreras CM. 2013. Chapter 2, Anxiety: an adaptive emotion. In: Durbano F, editor. Mental and behavioral disorders and diseases of the nervous system: new insight into anxiety disorders. Rijeka: InTech; p. 21–37.
   Google Scholar
• Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. 2003. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology. 45:293–303.
   PubMed Web of Science ®Google Scholar
• Heikkinen AE, Moykkynen TP, Korpi ER. 2009. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology. 34:290–298.
   PubMed Web of Science ®Google Scholar
• Hosie AM, Wilkins ME, da Silva HM, Smart TG. 2006. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature. 444:486–489.
   PubMed Web of Science ®Google Scholar
• Johns MW. 1977. Self-poisoning with barbiturates in England and Wales during 1959-74. Br Med J. 1:1128–1130.
   PubMed Web of Science ®Google Scholar
• Juif PE, Melchior M, Poisbeau P. 2015. Characterization of the fast GABAergic inhibitory action of etifoxine during spinal nociceptive processing in male rats. Neuropharmacology. 91:117–122.
   PubMed Web of Science ®Google Scholar
• Kruse HJ, Kuch H. 1985. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneimittelforschung. 35:133–135.
   PubMed Web of Science ®Google Scholar
• Kruse HJ, Kuch H. 1986. Potentiation of clobazam's anticonvulsant activity by etifoxine, a non-benzodiazepine tranquilizer, in mice. Comparison studies with sodium valproate. Arzneimittelforschung. 36:1320–1322.
   PubMed Web of Science ®Google Scholar
• Lader M, Scotto JC. 1998. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 139:402–406.
   PubMed Web of Science ®Google Scholar
• Leroy C, Poisbeau P, Keller AF, Nehlig A. 2004. Pharmacological plasticity of GABA(A) receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy. J Physiol. 557:473–487.
   PubMed Web of Science ®Google Scholar
• Longone P, di Michele F, D'Agati E, Romeo E, Pasini A, Rupprecht R. 2011. Neurosteroids as neuromodulators in the treatment of anxiety disorders. Front Endocrin. 2:55.
   PubMedGoogle Scholar
• Loomis WF, Behrens MM, Williams ME, Anjard C. 2010. Pregnenolone sulfate and cortisol induce secretion of acyl-CoA-binding protein and its conversion into endozepines from astrocytes. J Biol Chem. 285:21359–21365.
   PubMed Web of Science ®Google Scholar
• Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, Fritschy JM, Rulicke T, Bluethmann H, Mohler H, et al. 2000. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 290:131–134.
   PubMed Web of Science ®Google Scholar
• Lucki I. 1996. Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry. 57(Suppl 6):5–10.
   PubMed Web of Science ®Google Scholar
• McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, et al. 2000. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci.Neurosci3:587–592.
   PubMed Web of Science ®Google Scholar
• Moch C, Rocher F, Laine P, Lacotte J, Biour M, Gouraud A, Bernard N, Descotes J, Vial T. 2012. Etifoxine-induced acute hepatitis: a case series. Clin Res Hepatol Gastroenterol. 36:e85–e88.
   PubMed Web of Science ®Google Scholar
• Mohler H, Fritschy JM, Rudolph U. 2002. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 300:2–8.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. 2006. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol Clin Exp. 21:139–149.
   PubMed Web of Science ®Google Scholar
• Nothdurfter C, Rammes G, Baghai TC, Schule C, Schumacher M, Papadopoulos V, Rupprecht R. 2012. Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J Neuroendocrinol. 24:82–92.
   PubMed Web of Science ®Google Scholar
• Olsen RW. 2018. GABAA receptor: Positive and negative allosteric modulators. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.01.036
   Web of Science ®Google Scholar
• Olsen RW, Sieghart W. 2009. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 56:141–148.
   PubMed Web of Science ®Google Scholar
• Patchev VK, Shoaib M, Holsboer F, Almeida OF. 1994. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience. 62:265–271.
   PubMed Web of Science ®Google Scholar
• Pinna G, Costa E, Guidotti A. 2006. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl). 186:362–372.
   PubMed Web of Science ®Google Scholar
• Poisbeau P, Feltz P, Schlichter R. 1997. Modulation of GABAA receptor-mediated IPSCs by neuroactive steroids in a rat hypothalamo-hypophyseal coculture model. J Physiol. 500: 475–485.
   PubMed Web of Science ®Google Scholar
• Poisbeau P, Keller AF, Aouad M, Kamoun N, Groyer G, Schumacher M. 2014. Analgesic strategies aimed at stimulating the endogenous production of allopregnanolone. Front Cell Neurosci. 8:174.
   PubMed Web of Science ®Google Scholar
• Poisbeau P, Williams SR, Mody I. 1997. Silent GABAA synapses during flurazepam withdrawal are region-specific in the hippocampal formation. J Neurosci. 17:3467–3475.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Crawford D, Dellovade T, Savinainen A, Graham D, Liere P, Oudinet JP, Webb M, Hering H. 2016. Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of Multiple Sclerosis. Neuropharmacology. 108:229–237.
   PubMed Web of Science ®Google Scholar
• Reinhold JA, Mandos LA, Rickels K, Lohoff FW. 2011. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 12:2457–2467.
   PubMed Web of Science ®Google Scholar
• Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Mohler H. 1999. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 401:796–800.
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. 2010. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 9:971–988.
   PubMed Web of Science ®Google Scholar
• Sammler E, Titz S, Hormuzdi S. 2015. Neuronal chloride transport tuning. Lancet. 385(Suppl 1):S85.
   PubMed Web of Science ®Google Scholar
• Schlichter R, Rybalchenko V, Poisbeau P, Verleye M, Gillardin J. 2000. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology. 39:1523–1535.
   PubMed Web of Science ®Google Scholar
• Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R. 2011. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?. Neuroscience. 191:55–77.
   PubMed Web of Science ®Google Scholar
• Servant D, Graziani PL, Moyse D, Parquet PJ. 1998. [Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study]. Encephale. 24:569–574.
   PubMed Web of Science ®Google Scholar
• Shu HJ, Eisenman LN, Jinadasa D, Covey DF, Zorumski CF, Mennerick S. 2004. Slow actions of neuroactive steroids at GABAA receptors. J Neurosci Neurosci. 24:6667–6675.
   PubMed Web of Science ®Google Scholar
• Simon-O'Brien E, Gauthier D, Riban V, Verleye M. 2016. Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury. J Neuroinflammation. 13:203.
   PubMed Web of Science ®Google Scholar
• Stein DJ. 2015. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 32:57–68.
   PubMed Web of Science ®Google Scholar
• Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. 2003. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci U S A. 100:14439–14444.
   PubMed Web of Science ®Google Scholar
• Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, Rudolph U, Luscher C. 2010. Neural bases for addictive properties of benzodiazepines. Nature. 463:769–774.
   PubMed Web of Science ®Google Scholar
• Tan KR, Rudolph U, Luscher C. 2011. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 34:188–197.
   PubMed Web of Science ®Google Scholar
• Twyman RE, Macdonald RL. 1992. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J Physiol. 456:215–245.
   PubMed Web of Science ®Google Scholar
• Ugale RR, Sharma AN, Kokare DM, Hirani K, Subhedar NK, Chopde CT. 2007. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats. Brain Res. 1184:193–201.
   PubMed Web of Science ®Google Scholar
• Uzunov DP, Cooper TB, Costa E, Guidotti A. 1996. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci U S A. 93:12599–12604.
   PubMed Web of Science ®Google Scholar
• Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychenne B, Schumacher M, Gillardin JM. 2005. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav.82:712–720.
   PubMed Web of Science ®Google Scholar
• Verleye M, Dumas S, Heulard I, Krafft N, Gillardin JM. 2011. Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to overexpression of central GABAA receptor beta2 subunits? Eur Neuropsychopharmacol. 21:457–470.
   PubMed Web of Science ®Google Scholar
• Verleye M, Gillardin JM. 2004. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol Behav. 82:891–897.
   PubMed Web of Science ®Google Scholar
• Verleye M, Heulard I, Gillardin JM. 2009. The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice. Alcohol. 43:197–206.
   PubMed Web of Science ®Google Scholar
• Verleye M, Schlichter R, Gillardin JM. 1999. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. Neuroreport10:3207–3210.
   PubMed Web of Science ®Google Scholar
• Wang M, He Y, Eisenman LN, Fields C, Zeng CM, Mathews J, Benz A, Fu T, Zorumski E, Steinbach JH, et al. 2002. 3beta -hydroxypregnane steroids are pregnenolone sulfate-like GABA(A) receptor antagonists. J Neurosci. 22:3366–3375.
   PubMed Web of Science ®Google Scholar
• Wolf L, Bauer A, Melchner D, Hallof-Buestrich H, Stoertebecker P, Haen E, Kreutz M, Sarubin N, Milenkovic VM, Wetzel CH, et al. 2015 . Enhancing neurosteroid synthesis-relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry. 48:72–77.
   PubMed Web of Science ®Google Scholar
• Zeitler A, Kamoun N, Goyon S, Wahis J, Charlet A, Poisbeau P, Darbon P. 2016. Favouring inhibitory synaptic drive mediated by GABA(A) receptors in the basolateral nucleus of the amygdala efficiently reduces pain symptoms in neuropathic mice. Eur J Neurosci. 43:1082–1088.
   PubMed Web of Science ®Google Scholar
• Zhou X, He X, He B, Zhu Z, Zheng C, Xu J, Jiang L, Gu L, Zhu J, Zhu Q, et al. 2013. Etifoxine promotes glialderived neurotrophic factorinduced neurite outgrowth in PC12 cells. Mol Med Rep. 8:75–80.
   PubMed Web of Science ®Google Scholar
• Zhou X, He B, Zhu Z, He X, Zheng C, Xu J, Jiang L, Gu L, Zhu J, Zhu Q, et al. 2014. Etifoxine provides benefits in nerve repair with acellular nerve grafts. Muscle Nerve. 50:235–243.
   PubMed Web of Science ®Google Scholar